NZ717369A - Antibody titer-increasing agent using lactic acid bacterium - Google Patents

Antibody titer-increasing agent using lactic acid bacterium

Info

Publication number
NZ717369A
NZ717369A NZ717369A NZ71736914A NZ717369A NZ 717369 A NZ717369 A NZ 717369A NZ 717369 A NZ717369 A NZ 717369A NZ 71736914 A NZ71736914 A NZ 71736914A NZ 717369 A NZ717369 A NZ 717369A
Authority
NZ
New Zealand
Prior art keywords
antibody titer
increasing agent
lactic acid
acid bacterium
adjuvant
Prior art date
Application number
NZ717369A
Other languages
English (en)
Inventor
Seiya Makino
Jun Henmi
Hiroshi Kano
Yukio Asami
Shuji Ikegami
Hiroyuki Itou
Yoshio Suzuki
Sachio Kawai
Keisuke Sawaki
Ko Okumura
Isao Nagaoka
Kazuyoshi Takeda
Original Assignee
Meiji Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Meiji Co Ltd filed Critical Meiji Co Ltd
Publication of NZ717369A publication Critical patent/NZ717369A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A61K2039/55594—Adjuvants of undefined constitution from bacteria
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NZ717369A 2013-08-26 2014-08-26 Antibody titer-increasing agent using lactic acid bacterium NZ717369A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2013175048 2013-08-26
PCT/JP2014/072229 WO2015029967A1 (ja) 2013-08-26 2014-08-26 乳酸菌を用いた抗体価上昇剤

Publications (1)

Publication Number Publication Date
NZ717369A true NZ717369A (en) 2017-11-24

Family

ID=52586524

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ717369A NZ717369A (en) 2013-08-26 2014-08-26 Antibody titer-increasing agent using lactic acid bacterium

Country Status (10)

Country Link
US (1) US10195271B2 (ja)
EP (1) EP3040083B1 (ja)
JP (1) JP6449771B2 (ja)
CN (1) CN105555307A (ja)
AU (1) AU2014313030B2 (ja)
CA (1) CA2921820C (ja)
HK (1) HK1218387A1 (ja)
NZ (1) NZ717369A (ja)
SG (2) SG11201601185YA (ja)
WO (1) WO2015029967A1 (ja)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6713751B2 (ja) 2015-10-26 2020-06-24 キリンホールディングス株式会社 抗原に対する特異的な細胞傷害性ｔ細胞（ｃｔｌ）及び抗体産生を増強させる方法
JP6777911B2 (ja) * 2016-08-17 2020-10-28 株式会社明治 抗インフルエンザ薬による獲得免疫機能低下抑制用発酵乳およびその製造方法
JP7065589B2 (ja) * 2017-10-31 2022-05-12 株式会社明治 ＩＬ－１β血清濃度低下用発酵乳、ＣＸＣＬ１血清濃度低下用発酵乳、癌に伴うＩＬ－１βの過度な血清濃度上昇の抑制用発酵乳、または、癌に伴うＣＸＣＬ１の過度な血清濃度上昇の抑制用発酵乳
EP4297589A1 (en) * 2021-02-26 2024-01-03 Pantheryx, Inc. Stabilized colostrum compositions

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2911057B2 (ja) 1991-01-18 1999-06-23 高砂香料工業株式会社 感染防御剤及び感染防御効果を有する機能性食品
JP3805572B2 (ja) * 1999-07-27 2006-08-02 大和製罐株式会社 押し潰し容易なプラスチックボトル
JP5177728B2 (ja) 2003-12-12 2013-04-10 株式会社明治 Ｎｋ細胞活性化剤
JP3975361B2 (ja) * 2004-03-08 2007-09-12 愛媛県 抗ストレプトコッカスサーモフィラスモノクローナル抗体、その産生細胞、ストレプトコッカスサーモフィラスの検出方法及び検出試薬
ATE473636T1 (de) 2005-02-15 2010-07-15 Barry R Goldin Nahrungsmittel mit probiotischem und isoliertem beta-glukan und verwendungsverfahren dafür
FR2912657B1 (fr) 2007-02-16 2009-04-17 Gervais Danone Sa Utilisation de lactobacillus casei pour renforcer la protection induite par la vaccination anti-grippale.
CN102647991B (zh) * 2009-11-25 2015-05-06 株式会社明治 抗病毒剂和饮食品组合物
JP5242855B2 (ja) 2010-07-29 2013-07-24 国立大学法人北海道大学 免疫アジュバント
KR101806435B1 (ko) 2010-10-15 2017-12-07 시에이치알. 한센 에이/에스 면역보강제

Also Published As

Publication number Publication date
CN105555307A (zh) 2016-05-04
US20160206733A1 (en) 2016-07-21
EP3040083A4 (en) 2017-01-18
US10195271B2 (en) 2019-02-05
EP3040083B1 (en) 2018-11-21
JPWO2015029967A1 (ja) 2017-03-02
SG11201601185YA (en) 2016-03-30
AU2014313030A1 (en) 2016-04-07
HK1218387A1 (zh) 2017-02-17
SG10201810886YA (en) 2019-01-30
WO2015029967A1 (ja) 2015-03-05
EP3040083A1 (en) 2016-07-06
JP6449771B2 (ja) 2019-01-09
CA2921820C (en) 2021-10-12
AU2014313030B2 (en) 2017-01-19
CA2921820A1 (en) 2015-03-05

Similar Documents

Publication Publication Date Title
PH12014502855A1 (en) Attenuated streptococcus suis vaccines and methods of making and use thereof
AU2015296298A8 (en) Flagellin-based agents and uses including effective vaccination
EP3200831A4 (en) Vaccines having an antigen and interleukin-21 as an adjuvant
MX2022002106A (es) Formulaciones de vacuna de vial unico.
MX2014006630A (es) Vacuna a base toxina clostridium difficile.
PH12016501968A1 (en) Novel macrocyclic compounds
MX2016016746A (es) Composiciones de vacuna con adyuvante dual, preparacion y usos.
PH12015501716B1 (en) Anti-mycoplasma spp. subunit vaccine
NZ717369A (en) Antibody titer-increasing agent using lactic acid bacterium
EP3308800A4 (en) Adjuvant for vaccines, vaccine, and immunity induction method
TN2014000518A1 (en) Reassortant btv and ahsv vaccines
NZ741342A (en) Daptomycin formulations and uses thereof
WO2012003361A3 (en) Nanoemulsion vaccines
MX2019005535A (es) Streptococcus thermophilus para uso en la preparación de productos fermentados.
EP3165599A4 (en) Novel lactic acid bacterium and composition including said lactic acid bacterium
GB2515222A (en) Use of flagellin as a vaccine
PH12017500407A1 (en) Streptococcus agalactiae antigens associated with strains virulent in fish
WO2013173256A3 (en) New and improved influenza vaccines
GB2530210A (en) Novel piscirickettsia salmonis isolate
WO2014188212A3 (en) Treatment and prevention of malaria
SG191331A1 (en) Determination of the efficacy of an anti-mycobacterial vaccination
WO2016077382A3 (en) Conjunctivitis vaccines
PL409072A1 (pl) 4-etoksy-4'-metoksy-α, β-dihydrochalkon oraz sposób otrzymywania 4-etoksy-4'-metoksy-α. β-dihydrochalkonu
UA89485U (ru) Способ усиления иммунного ответа мимикринами из бактерий при вакцинации против вирусных и некоторых бактериальных инфекций
TH182464A (th) สารกระทำที่เพิ่มแอนติบอดี้ไทเทอร์(antibody titer) โดยการใช้แบคทีเรียที่ผลิตกรด แลคติก (lactic acid bacterium)

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 AUG 2019 BY DENNEMEYER + CO

Effective date: 20180803

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 AUG 2020 BY CPA GLOBAL

Effective date: 20190712

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 AUG 2021 BY CPA GLOBAL

Effective date: 20200709

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 AUG 2022 BY CPA GLOBAL

Effective date: 20210715

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 AUG 2023 BY CPA GLOBAL

Effective date: 20220715

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 AUG 2024 BY CPA GLOBAL

Effective date: 20230718